ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The emergence of resistant mutations within the ABL kinase domain of BCR-ABL1 is a well-established mechanism of TKI resistance in CML and Philadelphia-chromosome-positive ALL (Ph-pos ALL)30.